je.st
news
Tag: cancer
Second Baby Powder Ovarian Cancer Trial Opens in Missouri
2016-04-16 05:40:56| Food - Topix.net
Attorneys presented opening arguments in a jury trial to determine whether the talc in Johnson & Johnson's baby powder caused a 62-year-old woman's ovarian cancer. According to news reports, the plaintiff, Gloria Ristesund, was diagnosed with ovarian cancer in 2011 and had her uterus removed after decades of using Johnson's Baby Powder in her genital area.
Tags: baby
trial
cancer
missouri
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review
2016-04-13 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: review
application
head
license
For J&J Prostate Cancer Is PARP For The Course
2016-04-07 23:45:50| Food - Topix.net
Johnson & Johnson addressed two issues with one relatively small $35m payment: its position in prostate cancer and absence from PARP inhibition. The big pharma group locked up one of just two unpartnered assets in this rejuvenated class and has chosen to focus its work in prostate cancer, where Zytiga might soon run out of market exclusivity.
Tags: the
cancer
prostate
prostate cancer
Merck to Present New Data for KEYTRUDA (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
2016-04-06 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple tumor types, both as a single agent and in combination with other therapies, will be presented at this years American Association for Cancer Research (AACR) Annual Meeting in New Orleans, April 16 20. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestor:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
research
present
american
Powder all over body after shower leads to cancer?
2016-04-05 15:07:59| Biotech - Topix.net
Powder after shower habit may be lead to cancer, especially in the underpants or if powder has asbestos in it. what possibly caused her passing -- baby powder.
Sites : [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] next »